Related Experiment Video

Updated: Mar 1, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.3K

Treatment of congestive heart failure: experience with fosinopril

M Blumenthal1

  • 1Cardiovascular Clinical Research and Development, Bristol Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543-4000, USA.

American Journal of Hypertension
|November 20, 1997
PubMed

Insights

Congestive heart failure (CHF) is increasing, but treatments like ACE inhibitors, including the newer drug fosinopril, can reduce symptoms and slow progression. Fosinopril is effective and beneficial for patients with kidney issues, potentially preventing heart failure.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Congestive heart failure (CHF) prevalence is rising, significantly impacting quality of life and life expectancy.
  • Current CHF therapy aims to alleviate symptoms, enhance functional capacity, and impede disease progression.

Purpose of the Study:

  • To evaluate the efficacy of fosinopril, a novel angiotensin-converting enzyme (ACE) inhibitor, in managing congestive heart failure.
  • To compare fosinopril with existing treatments like enalapril.
  • To assess the benefits of fosinopril in patients with renal insufficiency and its potential role in CHF prevention.

Main Methods:

  • Comparative clinical evaluation of fosinopril against enalapril.
  • Assessment of therapeutic outcomes including symptom reduction and functional capacity improvement.
  • Analysis of pharmacokinetic properties, particularly the route of excretion, in patients with varying degrees of renal function.

Main Results:

  • Fosinopril demonstrates comparable efficacy to enalapril in treating CHF.
  • The dual and compensatory excretion route of fosinopril offers advantages for patients with renal insufficiency.
  • Fosinopril exhibits beneficial effects on cardiac function, suggesting a potential role in delaying the onset of overt heart failure.

Conclusions:

  • Fosinopril is an effective ACE inhibitor for managing congestive heart failure, offering advantages for patients with renal impairment.
  • Its favorable pharmacokinetic profile and positive effects on cardiac function position fosinopril as a valuable therapeutic option and potential preventative agent for CHF.

More Related Videos

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

7.5K
Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.7K

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
474
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
428
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.0K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.7K